AMERICAN JOURNAL OF NEURORADIOLOGY, vol.38, no.10, pp.1959-1965, 2017 (SCI-Expanded)
The authors assessed the clinical safety and efficacy of the Flow Re-Direction Endoluminal Device Jr (FRED Jr) dedicated to small-vessel diameters between 2.0 and 3.0 mm in 42 patients with 47 aneurysms. The primary efficacy end point of complete or near complete occlusion was reached at 1 month in 27/41 (66%), at 6 months in 21/27 (78%), and at 12 months in 11/11 (100%) aneurysms.